Literature DB >> 18584865

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab.

Clive S Zent1, Charla R Secreto, Betsy R LaPlant, Nancy D Bone, Timothy G Call, Tait D Shanafelt, Diane F Jelinek, Renee C Tschumper, Neil E Kay.   

Abstract

The mechanism of cytotoxicity of alemtuzumab and rituximab in chronic lymphocytic leukemia (CLL) is not well understood. We obtained fresh CLL cells from early-intermediate stage high-risk patients just prior to treatment with alemtuzumab and rituximab to study mechanisms of action and resistance. Alemtuzumab had minimal direct cytotoxicity but caused significant complement dependent cytotoxicity (CDC) although a subpopulation of CLL cells had intrinsic resistance. Rituximab had no direct cytotoxicity and caused minimal CDC in cells from most patients. These data suggest that CDC has a therapeutic role in patients treated with alemtuzumab and that measures to decrease resistance to CDC could increase efficacy.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18584865      PMCID： PMC2588544          DOI： 10.1016/j.leukres.2008.05.014

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  17 in total

1.  Clinical staging of chronic lymphocytic leukemia.

Authors:  K R Rai; A Sawitsky; E P Cronkite; A D Chanana; R N Levy; B S Pasternack
Journal:  Blood       Date:  1975-08       Impact factor: 22.113

Review 2.  Mechanisms of killing by anti-CD20 monoclonal antibodies.

Authors:  Martin J Glennie; Ruth R French; Mark S Cragg; Ronald P Taylor
Journal:  Mol Immunol       Date:  2007-09       Impact factor: 4.407

3.  The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction.

Authors:  John C Byrd; Shinichi Kitada; Ian W Flinn; Jennifer L Aron; Michael Pearson; David Lucas; John C Reed
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

4.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

Authors:  B D Cheson; J M Bennett; M Grever; N Kay; M J Keating; S O'Brien; K R Rai
Journal:  Blood       Date:  1996-06-15       Impact factor: 22.113

5.  Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

Authors:  J Golay; L Zaffaroni; T Vaccari; M Lazzari; G M Borleri; S Bernasconi; F Tedesco; A Rambaldi; M Introna
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

6.  The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism.

Authors:  Irene Munk Pedersen; Anne Mette Buhl; Pia Klausen; Christian H Geisler; Jesper Jurlander
Journal:  Blood       Date:  2002-02-15       Impact factor: 22.113

7.  Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium.

Authors:  Clive S Zent; James B Chen; Richard C Kurten; Gur P Kaushal; H Marie Lacy; Steven A Schichman
Journal:  Leuk Res       Date:  2004-05       Impact factor: 3.156

8.  Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Authors:  Gerard Lozanski; Nyla A Heerema; Ian W Flinn; Lisa Smith; Jennifer Harbison; Jennifer Webb; Mollie Moran; Margaret Lucas; Thomas Lin; Marcy L Hackbarth; John H Proffitt; David Lucas; Michael R Grever; John C Byrd
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

9.  Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells.

Authors:  Michael Stanglmaier; Simone Reis; Michael Hallek
Journal:  Ann Hematol       Date:  2004-08-07       Impact factor: 3.673

10.  Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.

Authors:  Stefan Faderl; Deborah A Thomas; Susan O'Brien; Guillermo Garcia-Manero; Hagop M Kantarjian; Francis J Giles; Charles Koller; Alessandra Ferrajoli; Srdan Verstovsek; Barbara Pro; Michael Andreeff; Miloslav Beran; Jorge Cortes; William Wierda; Ngoc Tran; Michael J Keating
Journal:  Blood       Date:  2003-01-09       Impact factor: 22.113
View more
  33 in total

1.  Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms.

Authors:  Kirstie L S Cleary; H T Claude Chan; Sonja James; Martin J Glennie; Mark S Cragg
Journal:  J Immunol       Date:  2017-04-12       Impact factor: 5.422

Review 2.  Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy.

Authors:  Carsten Denkert; Silvia Darb-Esfahani; Sibylle Loibl; Ioannis Anagnostopoulos; Korinna Jöhrens
Journal:  Semin Immunopathol       Date:  2011-04-17       Impact factor: 9.623

3.  CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity.

Authors:  Meisam Naeimi Kararoudi; Yuya Nagai; Ezgi Elmas; Marcelo de Souza Fernandes Pereira; Syed Abbas Ali; Philip Hollingsworth Imus; Darren Wethington; Ivan Marques Borrello; Dean Anthony Lee; Gabriel Ghiaur
Journal:  Blood       Date:  2020-11-19       Impact factor: 22.113

Review 4.  Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.

Authors:  Michael Campoli; Robert Ferris; Soldano Ferrone; Xinhui Wang
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

5.  In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis.

Authors:  Nohemi Salinas-Jazmín; Edith González-González; Luz X Vásquez-Bochm; Sonia M Pérez-Tapia; Marco A Velasco-Velázquez
Journal:  J Vis Exp       Date:  2017-05-04       Impact factor: 1.355

6.  Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.

Authors:  Frank J Beurskens; Margaret A Lindorfer; Mohammed Farooqui; Paul V Beum; Patrick Engelberts; Wendy J M Mackus; Paul W H I Parren; Adrian Wiestner; Ronald P Taylor
Journal:  J Immunol       Date:  2012-02-24       Impact factor: 5.422

Review 7.  Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells.

Authors:  Fabrizio Marcucci; Matteo Bellone; Cristiano Rumio; Angelo Corti
Journal:  MAbs       Date:  2012-12-04       Impact factor: 5.857

8.  Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.

Authors:  Nisar A Baig; Ronald P Taylor; Margaret A Lindorfer; Amy K Church; Betsy R LaPlant; Adam M Pettinger; Tait D Shanafelt; Grzegorz S Nowakowski; Clive S Zent
Journal:  J Immunol       Date:  2014-01-15       Impact factor: 5.422

Review 9.  Recent advances and novel treatment paradigms in acute lymphocytic leukemia.

Authors:  Nikolaos Papadantonakis; Anjali S Advani
Journal:  Ther Adv Hematol       Date:  2016-06-29

10.  A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy.

Authors:  Hongjie Wang; Ying Liu; Zong-Yi Li; Xiaolong Fan; Akseli Hemminki; André Lieber
Journal:  Blood       Date:  2009-11-12       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.